QIAGEN Launches Targeted RNA Panels for Next-generation Sequencing

Sample to Insight workflows deliver more efficient, accurate gene expression profiling

Feb 11, 2016, 09:30 ET from QIAGEN N.V.

HILDEN, Germany and GERMANTOWN, Maryland, February 11, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the introduction of more than 170 new QIAseq Targeted RNA Panels for gene expression profiling, expanding QIAGEN's portfolio of Sample to Insight solutions for next-generation sequencing (NGS). The panels enable researchers to select from over 20,000 human genes and lncRNA to survey expression fold changes and discover interactions between genes, cellular phenotypes and disease processes.

The new QIAseq Targeted RNA Panels use innovative molecular barcode technology and built-in control assays to empower researchers with true digital RNA sequencing and accurate gene expression results. Coupled with world-leading RNA isolation technologies, integrated NGS library preparation and Ingenuity® Pathway Analysis™ software, the panels provide a unique Sample to Insight solution for efficient RNA sequencing, using any NGS sequencer. Data analysis and insights are integrated into the QIAseq panels with easy-to-use, comprehensive analysis modules that require no bioinformatics expertise.

"Our QIAseq panels make RNA sequencing more accurate and reproducible with molecular barcode-based sequencing addressing the challenges posed by low-abundance transcripts, PCR duplicates and amplification bias. These are important new tools for NGS researchers," said Brad Crutchfield, Senior Vice President and head of QIAGEN's Life Sciences Business Area. "QIAGEN is leading the way in providing NGS solutions to take labs from Sample to Insight."

QIAseq Targeted RNA Panels cover an extensive range of disease- and signaling pathway-focused genes, with each panel targeting 100 to 500 genes. The content is based on the latest recommendations from relevant medical and scientific literature. The panels also can be customized to include other genes of clinical and biological interest, with flexibility to analyze from 12 to 1,000 genes simultaneously.

QIAGEN has collaborated with key leaders in genomic discovery in the development of the new QIAseq panels to validate product performance in a wide range of applications, including translational and clinical research. Dr. Chris Mason, Associate Professor at Weill Cornell Medicine and one of the early users of QIAseq Targeted RNA Panels, will be presenting application data of the new panels at the Advances in Genome Biology and Technology (AGBT) meeting in Orlando, Fla., on February 11.

QIASeq panel technology combines the flexibility and throughput of NGS with the accuracy of qPCR. The panels use only 20 nanograms of starting RNA material to analyze hundreds of genes. The molecular barcode technology, proprietary assay design algorithms and chemistry provide industry-leading specifications: >97% specificity (reads on target), >95% uniformity (bases covered by at least 20% of the mean coverage depth), and sensitivity to detect 1 RNA copy per cell for QIAseq RNA panels.

QIAGEN serves next-generation sequencing customers worldwide with solutions from Sample to Insight. The company's sample preparation workflows, including tools for difficult challenges such as single-cell analysis and studies of microbial diversity, are the industry's most respected. Its Enzymatics products are used in an estimated 80% of all NGS workflows. QIAGEN also provides a portfolio of NGS oncology gene panels compatible with any platform. The GeneReader NGS System was launched in late 2015 as the world's first truly Sample to Insight NGS workflow from primary sample to final report - providing a simpler, more cost-effective way for clinical testing to take advantage of NGS technology and improve outcomes.

About QIAGEN 

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products inapplied testing, personalized healthcare, clinical research,proteomics, women's health/HPV testing andnucleic acid-basedmolecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Contacts: QIAGEN Investor Relations John Gilardi e-mail: ir@QIAGEN.com +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: pr@QIAGEN.com +49-2103-29-11826

SOURCE QIAGEN N.V.